Lung cancer immunotherapy.
Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies, some of which generate active immune responses against tumor-associated antigens. Understanding the mechanisms of anti-tumor immunity and identifying target antigens will likely improve these therapeutic strategies and provide them with a niche in the future of lung cancer therapy.
Raez
Luis E
LE
Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA. lraez@med.miami.edu
Fein
Steven
S
Podack
Eckhard R
ER
D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry; D001500:BCG Vaccine / Q000737:chemistry; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008954:Models, Biological
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D019496:Cancer Vaccines